Biogen Amevive Requires More Study For Multiple Cycles Of Therapy
Executive Summary
Additional examination of multi-course therapy with Biogen's antipsoriatic Amevive should be conducted to create a more robust picture of long-term risk, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee suggested May 23
You may also be interested in...
Amevive “complete response” letter
Biogen receives "complete response" letter for its antipsoriatic therapy Amevive (alefacept) on June 6. The letter asks for further "clarification and information" related to Amevive data already submitted by Biogen. Firm will not be required to conduct additional studies for approval, despite request for additional examination of Amevive safety profile in multi-cycle therapy by an FDA advisory committee. The committee voted 8-2 with one abstention for approval in moderate to severe psoriasis May 23 (1"The Pink Sheet" June 3, p. 22)...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011